Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDRevance Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.25 | -$0.23 | -$0.24 |
| Q2 2025 | 1 | -$0.19 | -$0.17 | -$0.18 |
| Q3 2025 | 1 | -$0.11 | -$0.10 | -$0.11 |
| Q4 2025 | 1 | -$0.08 | -$0.08 | -$0.08 |
Revance Therapeutics, Inc. Earnings Date And Information
Revance Therapeutics, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.37 earnings per share for the quarter, missing analysts' consensus estimates of $-0.35 by $0.02. The company had revenue of 59.88 M for the quarter and had revenue of 234.04 M for the year. Revance Therapeutics, Inc. has generated $-4 earnings per share over the last year ($-3.83 diluted earnings per share) and currently has a price-to-earnings ratio of -1.75. Revance Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Revance Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.35 | -$0.34 | 0.01 | $68.17 M | $59.88 M |
| 08/08/2024 | Q2 2024 | -$0.48 | -$0.36 | 0.12 | $66.30 M | $65.39 M |
| 05/09/2024 | Q1 2024 | -$0.66 | -$0.58 | 0.08 | $51.94 M | |
| 12/30/2023 | Q4 2023 | -$0.62 | $69.80 M | |||
| 11/08/2023 | Q3 2023 | -$1.02 | -$1.63 | -0.61 | $58.40 M | $56.78 M |
| 08/08/2023 | Q2 2023 | -$0.72 | -$0.80 | -0.08 | $58.71 M | $58.13 M |
| 05/09/2023 | Q1 2023 | -$0.75 | -$0.81 | -0.06 | $49.33 M | |
| 02/28/2023 | Q4 2022 | -$1.04 | -$1.80 | -0.76 | $49.92 M | |
| 11/08/2022 | Q3 2022 | -$0.85 | -$1.17 | -0.32 | $28.24 M | $29.02 M |
| 08/09/2022 | Q2 2022 | -$0.91 | -$0.88 | 0.03 | $28.15 M | $28.37 M |
| 05/10/2022 | Q1 2022 | -$0.91 | -$0.94 | -0.03 | $25.26 M | |
| 02/28/2022 | Q4 2021 | -$0.98 | -$0.93 | 0.05 | $25.95 M | |
| 11/09/2021 | Q3 2021 | -$1.15 | -$1.10 | 0.05 | $20.07 M | $19.75 M |
| 08/05/2021 | Q2 2021 | -$1.14 | -$1.07 | 0.07 | $15.50 M | $18.80 M |
| 05/10/2021 | Q1 2021 | -$1.19 | -$1.08 | 0.11 | $13.30 M | |
| 02/25/2021 | Q4 2020 | -$1.24 | $11.13 M | |||
| 11/09/2020 | Q3 2020 | -$1.09 | -$1.34 | -0.25 | $1.84 M | $3.84 M |
| 08/06/2020 | Q2 2020 | -$0.96 | -$1.12 | -0.16 | $508,125 | $299,000 |
| 05/07/2020 | Q1 2020 | -$0.91 | -$1.15 | -0.24 | $58,000 | |
| 02/26/2020 | Q4 2019 | -$0.99 | $89,000 |
Revance Therapeutics, Inc. Earnings: FAQ's
When is Revance Therapeutics, Inc.'s earnings date?
Revance Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
How can I listen to Revance Therapeutics, Inc.'s earnings conference
call?
The conference call for Revance Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read Revance Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Revance Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does Revance Therapeutics, Inc. generate each year?
Revance Therapeutics, Inc. (:RVNC) has a recorded annual revenue of $234.04 M.
How much profit does Revance Therapeutics, Inc. generate each year?
Revance Therapeutics, Inc. (:RVNC) has a recorded net income of $234.04 M. Revance Therapeutics, Inc. has generated $-3.83 earnings per share over the last four quarters.
What is Revance Therapeutics, Inc.'s price-to-earnings ratio?
Revance Therapeutics, Inc. (:RVNC) has a price-to-earnings ratio of -1.75 and price/earnings-to-growth ratio is -0.04.